Combination of vasculature targeting, hypofractionated radiotherapy, and immune checkpoint inhibitor elicits potent antitumor immune response and blocks tumor progression.
Stefano PieriniAbhishek MishraRenzo Perales-LinaresMireia Uribe-HerranzSilvia BeghiAndrea GiglioSergei PustylnikovFrancesca CostabileStavros RafailAugusto AmiciJohn G FacciponteCostantinos KoumenisAndrea FacciabenePublished in: Journal for immunotherapy of cancer (2021)
Our findings describe novel cooperative mechanisms between heterologous TEM1 vaccination and RT, highlighting the pivotal role that TAA cross-priming plays for an effective antitumor strategy. Furthermore, we provide rationale for using heterologous TEM1 vaccination and RT as an add-on to immune checkpoint blockade as triple combination therapy into early-phase clinical trials.
Keyphrases
- combination therapy
- clinical trial
- immune response
- radiation therapy
- early stage
- saccharomyces cerevisiae
- poor prognosis
- locally advanced
- cancer therapy
- radiation induced
- phase ii
- squamous cell carcinoma
- dendritic cells
- small cell lung cancer
- randomized controlled trial
- drug delivery
- long non coding rna
- brain metastases
- rectal cancer